TY - JOUR
T1 - Managed Clinical Network for esophageal cancer enables reduction of variation between hospitals trends in treatment strategies, lead time, and 2-year survival
AU - van Hoeve, Jolanda C.
AU - Verhoeven, Rob H. A.
AU - Nagengast, Wouter B.
AU - Oppedijk, Vera
AU - Lynch, Mitchell G.
AU - van Rooijen, Johan M.
AU - Veldhuis, Patrick
AU - Siesling, Sabine
AU - Kouwenhoven, Ewout A.
N1 - Funding Information: We want to thank the former board of the MCN esophagogastric cancer in the North East region of the Netherlands and other involved health care professionals for their help and input in the early phase of this evaluation: M.B. Polée, medical oncologist, Medical Center Leeuwarden; D.P. Woutersen, radiation oncologist, Medical Center Twente; R. Hoekstra, medical oncologist, Hospital Group Twente; B.E. Schenk, gastroenterologist, Isala Hospital; A. Epping, nurse practitioner, Gelre Hospital; J.T.M. Plukker, surgical oncologist, University Medical Center Groningen; W. Kelder, surgical oncologist, Martini Hospital. Publisher Copyright: © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology
PY - 2023/1
Y1 - 2023/1
N2 - Introduction: Despite evidence-based guidelines, variation in esophageal cancer care exists in daily practice. Many oncology networks deployed regional agreements to standardize the patient care pathway and reduce unwarranted clinical variation. The aim of this study was to explore the trends in variation of esophageal cancer care between participating hospitals of the Managed Clinical Network (MCN) in the Netherlands. Materials and methods: Patients with esophageal cancer diagnosed from 2012 to 2016 were selected from the Netherlands Cancer Registry. Variation on treatment strategies, lead time to start of treatment, and 2-year survival, were calculated and compared between five clusters of hospitals within the network. Results: A total of 1763 patients, diagnosed in 17 hospitals, were included. 71% of all patients received treatment with a curative intent, which ranged from 69% to 77% between the clusters of hospitals in 2015–2016. Although variation in treatment modalities between the clusters was observed in 2012–2014, no significant variation existed in 2015–2016, except for patients receiving no treatment at all. The 2-year overall survival of patients receiving treatment with a curative intent did not vary significantly between the clusters of hospitals (range: 56%–63%). Nevertheless, the median lead time before patients started treatment with a curative intent varied between clusters of hospitals in 2015–2016 (range: 34–47 days; p < 0.001). Conclusion: Limited variation in esophageal cancer treatment between clusters of hospitals in the MCN existed. This study shows that oncology networks can promote standardization of cancer care and reduce variation between hospitals through insight into variation.
AB - Introduction: Despite evidence-based guidelines, variation in esophageal cancer care exists in daily practice. Many oncology networks deployed regional agreements to standardize the patient care pathway and reduce unwarranted clinical variation. The aim of this study was to explore the trends in variation of esophageal cancer care between participating hospitals of the Managed Clinical Network (MCN) in the Netherlands. Materials and methods: Patients with esophageal cancer diagnosed from 2012 to 2016 were selected from the Netherlands Cancer Registry. Variation on treatment strategies, lead time to start of treatment, and 2-year survival, were calculated and compared between five clusters of hospitals within the network. Results: A total of 1763 patients, diagnosed in 17 hospitals, were included. 71% of all patients received treatment with a curative intent, which ranged from 69% to 77% between the clusters of hospitals in 2015–2016. Although variation in treatment modalities between the clusters was observed in 2012–2014, no significant variation existed in 2015–2016, except for patients receiving no treatment at all. The 2-year overall survival of patients receiving treatment with a curative intent did not vary significantly between the clusters of hospitals (range: 56%–63%). Nevertheless, the median lead time before patients started treatment with a curative intent varied between clusters of hospitals in 2015–2016 (range: 34–47 days; p < 0.001). Conclusion: Limited variation in esophageal cancer treatment between clusters of hospitals in the MCN existed. This study shows that oncology networks can promote standardization of cancer care and reduce variation between hospitals through insight into variation.
KW - Esophageal cancer
KW - Oncology network
KW - Variation
UR - http://www.scopus.com/inward/record.url?scp=85135777101&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejso.2022.07.022
DO - https://doi.org/10.1016/j.ejso.2022.07.022
M3 - Article
C2 - 35963750
SN - 0748-7983
VL - 49
SP - 106
EP - 112
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 1
ER -